Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02800863 · ClinicalTrials.gov registry record
TARGET Post-Approval Study
A clinical trial, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- 426
- Enrollment target
NCT02800863 is a clinical trial that has completed, run by Abbott Medical Devices. The registered enrollment target is 426 participants.
The verdict
NCT02800863 has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- 426 participants
- Enrollment target
Study Summary
The purpose of this prospective, multicenter, single arm post-approval study is to demonstrate continued safety of the Axium and Proclaim Neurostimulator System for dorsal root ganglion (DRG) stimulation. The primary endpoint is the 12-month serious adverse event rate for permanent implants.
Interventions
- DEVICE Dorsal Root Ganglion (DRG) Stimulation (Axium™ Neurostimulator System)
- DEVICE Dorsal Root Ganglion (DRG) Stimulation (Proclaim™ Neurostimulator System)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 426 participants |
| Start Date | 2016-08-23 |
| Est. Completion | 2021-09-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02800863
The ClinicalTrials.gov registry entry for NCT02800863 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 426 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dorsal Root Ganglion (DRG) Stimulation (Axium™ Neurostimulator System) is the first listed.
NCT02800863 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02800863 about?
NCT02800863 is a clinical study titled "TARGET Post-Approval Study". The purpose of this prospective, multicenter, single arm post-approval study is to demonstrate continued safety of the Axium and Proclaim Neurostimulator System for dorsal root ganglion (DRG) stimulation. The primary endpoint is the 12-month serious adverse event rate for permanent implants.
What is the current status of trial NCT02800863?
This trial is currently completed. The enrollment target is 426 participants. The study started on 2016-08-23. Estimated completion is 2021-09-23.
What interventions are being tested in trial NCT02800863?
The interventions under investigation include: Dorsal Root Ganglion (DRG) Stimulation (Axium™ Neurostimulator System) (DEVICE), Dorsal Root Ganglion (DRG) Stimulation (Proclaim™ Neurostimulator System) (DEVICE).
Who is sponsoring clinical trial NCT02800863?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.